Evidence map›Paper›PMID 40579780›Full record

ArticleClinical and translational medicine2025

T-cell differentiation stage block bias confers hypermethylation and mediastinal preference in T-cell lymphoblastic lymphoma.

Jiali Wang, Bo Qian, Xiaowen Yu, Yidan Zhang, Chunlei Zhou, Tingting Yang, Le Xia, Gang Zhang, Yi-Xuan Zhang, Yaping Wang and 1 more

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiali WangDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Bo QianDepartment of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.
Xiaowen YuInflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, China.
Yidan ZhangDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Chunlei ZhouDepartment of Pathology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Tingting YangSchool of Tianyuan Honors, Nanjing Medical University, Nanjing, China.
Le XiaSchool of Tianyuan Honors, Nanjing Medical University, Nanjing, China.
Gang ZhangDepartment of Neurology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Yi-Xuan ZhangMedical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, China, School of Pharmacy, Nanjing Medical University, Nanjing, China.ORCID 0000-0001-9781-6281
Yaping WangDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Yongjun FangDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.

Funding

Jiangsu Funding Program for Excellent Postdoctoral Talent 2022ZB431Jiangsu Funding Program for Excellent Postdoctoral Talent 2023ZB043Nanjing Medical Science and Technology Development Project YKK23165Nanjing Postdoctoral Research Funding Program 323721National Natural Science Foundation of China 82204352Technology Development Foundation of Nanjing Medical University NMUB20220015
6 · The paper itself

Abstract

backgroundThe clinical guideline classifies T-LBL and T-ALL jointly, differentiating them merely by the bone marrow blast cell proportion. However, their distinct clinical manifestations, genetic profiles, and specific pathogenic requirements have prompted us to reevaluate the differences between them. METHODS AND

resultsWe established the NCH-TALL-LBL cohort, which includes flow cytometry data and somatic mutation data from our center. Additionally, we collected T-LBL samples and implemented single-cell RNA sequencing and single-cell T-cell receptor sequencing. Combining the single-cell RNA sequencing data of T-ALL, expression array data, flow cytometry data, we discovered that malignant T cells in T-LBL are predominantly in the DN- and DP-stage blocking modes (DP cells dominate). This block mode in T-LBL generates signals that drive the development of an immunosuppressive microenvironment and the mediastinum preference. Additionally, E2F2, an active transcription factor in the DP and DN stages, upregulates the expression of UHRF1, resulting in hypermethylation of tumor suppressor genes. Findings from in vivo and in vitro research clearly show that demethylation therapy targeting this mechanism effectively inhibits tumor proliferation in T-LBL.

conclusionFrom the perspective of differentiation blockage, T-LBL and T-ALL represent different stages of the same disease, and the stage block bias of T-cell contributes to their heterogeneity. KEY POINTS: Malignant T cells in T-LBL are primarily blocked in the DN and DP stages, which contributes to the immunosuppressive TME and mediastinum preference of T-LBL. The active transcription factor E2F2 in the DP and DN stages upregulates UHRF1 expression, leading to the hypermethylation of tumor suppressor genes in T-LBL. Demethylation therapy targeting the hypermethylation of tumor suppressor genes mediated by UHRF1 effectively inhibits tumor proliferation in T-LBL.

Indexed as

Cell DifferentiationDNA MethylationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaT-LymphocytesFemaleHumansMaleMediastinumhypermethylationmediastinum preferenceT‐cell differentiation stageT‐cell lymphoblastic lymphoma

Identifiers

PMID40579780
PMCPMC12205001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.